Fresenius Medical Care Reports Strong Underlying Q2 2026 Results and Continues €1BN Share Buyback
FMS sits 20% above its 52-week low of $20.02 on elevated volume (1.8× avg).
Summary
Fresenius Medical Care AG filed its full Q2 2026 interim financial report, showing strong underlying operating income growth and continued execution of its €1 billion share buyback program, despite a negative impact from a drug marketing authorization revocation.
Key Events · Earnings and Guidance · FMS
-
Strong Underlying Q2 2026 Financial Performance
Operating income increased by 10% to €466 million (15% at constant currency) for Q2 2026 compared to Q2 2025. Net income attributable to shareholders, while down 3% as reported, increased by 3% at constant currency to €218 million, and basic EPS rose 6% (13% at constant currency) to €0.81.
-
Continuation of €1 Billion Share Buyback Program
The company is actively executing its new €1 billion share buyback program, launched on May 28, 2026. The first tranche, amounting to up to €600 million, is expected to be completed by December 15, 2026. As of June 30, 2026, 2,454,945 shares were repurchased under this program.
-
Negative Impact from TAVNEOS® Marketing Authorization Revocation
A €71 million negative impact on income from equity method investees was recorded for Q2 2026 due to the European Medicines Agency's recommended revocation of TAVNEOS® marketing authorization.
-
No Goodwill Impairment Indication
Despite the company's market capitalization being lower than its shareholders' equity, an impairment test performed as of June 30, 2026, concluded there was no indication of goodwill impairment, signaling stability in asset valuations.
Analysis · FMS · Industrial Applications And Services
This 6-K provides the full unaudited interim financial statements for Q2 2026, detailing a strong underlying operational performance. Operating income grew significantly at constant currency, and the company continues its substantial share buyback program, signaling confidence in its valuation. While a specific negative impact from a drug marketing authorization revocation was noted, the overall financial health appears robust, further supported by a positive goodwill impairment test result.
At the time of this filing, FMS was trading at $24.10 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $13.7B. The 52-week trading range was $20.02 to $27.64. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.